Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results for the third quarter ended September 30, 2007 and operational highlights.

"The third quarter of 2007 marked an important transition for Anadys," said Steve Worland, Ph.D., President and Chief Executive Officer of Anadys. "We elected to focus investment on our two product candidates we believe most likely to create value, ANA598 for hepatitis C virus infection and ANA773 in oncology. Concurrently, we discontinued development of ANA975 and ANA380 and ceased early discovery efforts."

"We decided to focus on ANA598 and ANA773 based on the demonstrated preclinical properties of these compounds and our anticipation of future clinical benefits," continued Dr. Worland. "We are pleased to announce today that our IND to commence clinical investigation of ANA773 has been accepted by the FDA and we look forward to initiating a trial in cancer patients by the end the year. In parallel, we continue to advance ANA598 through IND enabling studies. We believe that our decision to focus investment on these two product candidates will enable us to achieve meaningful clinical milestones in both programs with our existing cash reserves."

Financial Results

In the third quarter, the Company and its collaborator, Novartis, decided to discontinue the development of ANA975, a Phase 1b compound for the treatment of hepatitis C virus (HCV) infection. Also during the third quarter, Novartis and Anadys concluded that no further activities will be pursued under the c
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 SonaCare ... Focused Ultrasound (HIFU) devices, recently participated in the ... Renal Mass 360° .” Key opinion leaders in ... advances related to small renal masses while attendees ... different ablative technologies in hands-on labs. Attendees at ...
(Date:11/26/2014)... West Chester, OH (PRWEB) November 25, 2014 ... International Holdings, has joined the Graphel Carbon Products team ... experience in sales, marketing, and customer service for the ... to add Miles to our team,” stated Dave Trinkley, ... Products. “His wide range of experience in the ...
(Date:11/26/2014)... , Nov. 25, 2014 Bio-Techne Corporation (NASDAQ: ... appointed Robert Gavin to serve in a ... Protein Platforms Division.  Mr. Gavin will be responsible for ... which includes the ProteinSimple business acquired in July 2014 ... San Jose, California -based ProteinSimple develops and ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... NEW YORK, June 23 Medicsight PLC, a,subsidiary of ... an industry,leader in the development of Computer-Aided Detection (CAD) ... and Lucan Toh,(Director of Business Development) will be presenting ... 24th June., The conference will be held from ...
... Cystinosis Foundation Ireland to Host Event June 27-28, ... Corp. ("Raptor" or the "Company") (OTC Bulletin Board:,RPTP), ... clinical,division, will present at the Cystinosis Foundation Ireland,s ... 2008 at the,Hilton Hotel, Dublin City, Charlemont Place, ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... services, today announced Health Canada -- Medical,Device ... of the ATS,Open Pivot(R) AP360(TM) Mechanical Heart ... The ATS AP360 heart valve maximizes ...
Cached Biology Technology:Medicsight to Present at Piper Jaffray Annual Europe Conference 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 3Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 4Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 5ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve 2
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
(Date:11/5/2014)... diversity in their ability to identify scents and odors. ... their perceptual evaluation of odors, with women outperforming men ... Sex differences in olfactory detection may play a role ... one,s perception of smell, which is naturally linked to ... been suggested to be cognitive or emotional, rather than ...
(Date:11/4/2014)... the right amount of death at the right time ... to new research that could help in understanding animal ... , In a paper in the journal Trends ... and European colleagues conclude that the kind of positive ... of individuals, or mortality, depends on the size and ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2
... gene that contributes to insulin resistance appears to prevent ... researchers say. Cardiovascular disease is the biggest health ... trying to understand why have knocked out protein tyrosine ... get diabetes. "Even before you have really bad ...
... to move swiftly to pass economic recovery legislation ... including the National Science Foundation (NSF), the Department ... and Space Administration (NASA), and National Institute of ... of the American Recovery and Reinvestment Act included ...
... National Institute of Standards and Technology (NIST) has ... be an important quality assurance tool for measuring ... in dietary supplements. The new Standard Reference Material ... collaboration with the Office of Dietary Supplements (ODS) ...
Cached Biology News:Decreasing insulin resistance prevents obesity-related cardiovascular damage 2Decreasing insulin resistance prevents obesity-related cardiovascular damage 3Basic research critical to America's economic recovery 2New reference material can improve testing of multivitamin tablets 2